Turoctocog alfa

Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was first launched in Germany in January 2014 and has been approved in the US, EU and Japan.